Protagonist Therapeutics, Inc. Common Stock (PTGX) Stock
Key stats
- Market cap
- $8.80B
- Price / Earnings ratio
- 26.0x
- EPS (TTM)
- $5.15
- Volume
- Loading
- 52-week high
- $160.81
- 52-week low
- $77.00
Source: third-party data provider, as of November 13, 2026
Compare with PTGX
Recent news

Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
PTGX

Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-Term
Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-Term
PTGX

Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
PTGX

Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know
PTGX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 43.79
- MACD 12/26/9
- -1.29
- EMA 9 of MACD
- -0.79
- MACD histogram
- -0.50
- SMA 50
- $140.89
- Price below SMA 50
- EMA 50
- $139.42
- Price below EMA 50
- SMA 200
- $118.77
- Price above SMA 200
- EMA 200
- $119.11
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
PTGX

Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-Term
Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-Term
PTGX

Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
PTGX

Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know
PTGX

Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
PTGX

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
PTGX

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
PTGX

Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock
Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock
PTGX

Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates
Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates
PTGX

Best Momentum Stocks to Buy for July 13th
Best Momentum Stocks to Buy for July 13th
PTGX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Protagonist Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Dinesh V. Patel Ph.D. | CEO, President, Secretary & Director | 1957 |
| Mr. Asif Ali | Executive VP & CFO | 1974 |
| Dr. Arturo M. Molina FACP, M.D., M.S. | Chief Medical Officer | 1959 |
| Mr. Venkat Thalladi Ph.D. | EVP & Chief Technical Officer | — |
| Dr. Newman Yeilding M.D. | Executive VP, Chief Scientific Officer | — |
| Mr. Matthew M. Gosling J.D. | Executive VP and Chief Legal & Business Officer | 1971 |
| Ms. Carena Spivey | Executive VP & Chief Human Resources Officer | — |
| Dr. Ashok Bhandari Ph.D. | EVP & Chief Discovery Officer | 1964 |
| Mr. Carter J. King | Executive Vice President of Business Development | 1971 |
| Ms. Abha Bommireddi | Executive VP & Chief of Staff | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 43.79
- MACD 12/26/9
- -1.29
- EMA 9 of MACD
- -0.79
- MACD histogram
- -0.50
- SMA 50
- $140.89
- Price below SMA 50
- EMA 50
- $139.42
- Price below EMA 50
- SMA 200
- $118.77
- Price above SMA 200
- EMA 200
- $119.11
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $160.00
- Average
- $186.17
- High
- $221.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -5.9 | +10.6 | ||||||||||
| 2022 | -17.1 | -19.7 | -9.8 | -62.4 | -9.5 | -7.3 | +26.6 | -11.5 | -8.2 | -5.6 | -6.5 | +39.9 |
| 2023 | +23.3 | +15.4 | +47.0 | -1.0 | +10.7 | +0.5 | -13.0 | +4.2 | -14.6 | -11.0 | +20.5 | +23.5 |
| 2024 | +6.8 | +6.5 | -10.0 | -11.2 | +10.1 | +16.2 | +6.4 | +13.0 | +8.7 | +3.3 | -6.3 | -10.8 |
| 2025 | -3.0 | +1.0 | +25.6 | -2.3 | +5.5 | +10.2 | +7.3 | +9.7 | +12.9 | +22.8 | +18.5 | +2.0 |
| 2026 | -6.2 | +10.9 | +11.8 | -4.5 | +1.2 | +29.1 | +9.2 | +11.7 | -3.8 | +4.1 | -3.2 |



